Liquid Nitric Oxide Releasing Solutions for Extended Wound Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for delivering nitric oxide (NO) to treat wounds and infections are inefficient, messy, painful, or require prolonged patient confinement due to short duration of action and need for multiple applications, and are not suitable for ambulatory patients or situations where the treatment site differs from the administration site.
Innovation Solution
A liquid nitric oxide releasing solution (NORS) that provides an extended release of gaseous NO by combining low concentrations of nitrite and an acidifying agent, allowing quick delivery and prolonged therapeutic effect at the treatment site, even when the administration and treatment sites are distinct.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If direct exposure to nitric oxide gas is used to treat wound infections, then effective antimicrobial action is achieved, but the patient must be connected to a gas cylinder for 8 hours at a time
Solution Approach 1:
The invention changes the physical state of nitric oxide from gas to liquid solution form, and modifies the delivery method from direct gas exposure requiring prolonged connection to a liquid solution that can be administered quickly and provides extended release of nitric oxide at the treatment site, thereby reducing treatment duration while maintaining efficacy
Solution Approach 2:
The invention introduces a liquid solution as an intermediary carrier that delivers nitric oxide to the treatment site. This liquid intermediary allows for controlled release of nitric oxide gas at the target location, eliminating the need for direct connection to gas cylinders and enabling ambulatory treatment
2Reliability
If existing NO donor preparations are used, then antimicrobial action is provided, but toxic side effects occur from carrier compounds and acidic environment
Solution Approach 1:
The invention changes the chemical parameters of the nitric oxide delivery system by using a liquid solution with controlled pH and composition, eliminating the need for strongly acidic environments required by traditional NO donors, thereby reducing toxic side effects while maintaining antimicrobial efficacy
Solution Approach 2:
The invention extracts and eliminates the harmful carrier compounds from traditional solid, liquid, or cream-based NO donors, using a simplified liquid solution formulation that provides nitric oxide delivery without the toxic side effects associated with conventional carrier systems
3Reliability
If endogenous approaches such as NOS stimulation or NO-donor dressings are used, then wound healing is targeted, but consistent steady-state concentrations of NO cannot be released
Solution Approach 1:
The invention provides continuous and consistent release of nitric oxide through the liquid solution formulation, maintaining steady-state concentrations at the treatment site. The liquid medium ensures sustained delivery compared to solid dressings or endogenous approaches that fail to maintain consistent levels
Solution Approach 2:
The invention optimizes the chemical parameters of the nitric oxide delivery system by using a liquid solution that enables controlled and consistent release rates, achieving stable steady-state concentrations that neither endogenous NOS stimulation nor traditional NO-donor dressings can reliably provide
4Ease of operation
If topical application methods are used for NO formation, then treatment can be administered to lesions, but short duration exposure requires multiple reapplications
Solution Approach 1:
The liquid nitric oxide solution provides extended release and prolonged exposure at the treatment site, eliminating the need for multiple reapplications. The continuous action of the liquid formulation maintains therapeutic nitric oxide levels throughout the treatment period
Solution Approach 2:
The invention changes the delivery parameters from short-duration topical application to extended-release liquid solution, increasing the duration of action while maintaining ease of topical administration. This allows single-application treatment rather than multiple reapplications
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The NORS enables effective, prolonged delivery of NO to treat wounds and infections without requiring continuous patient confinement, allowing ambulatory treatment and targeting sites distant from administration, with antibacterial, antifungal, and antiviral properties.
Implementation Method 1
combining low concentrations of nitrite and an acidifying agent to produce NO on the skin surface
Implementation Method 2
NO is a free-radical which is lipophilic with a small stokes radius making it an excellent signally molecule enabling it to readily cross the plasma membrane into the cytosol
Data Source
AI summary
The present invention relates to a liquid nitric oxide releasing solution (NORS) comprised of at least one nitric oxide releasing compound and at least one acidifying agent, wherein the NORS provides an extended release of a therapeutically effective amount of nitric oxide gas (gNO). The present invention also relates to a liquid NORS comprised of at least one nitrite compound having a concentration of no greater than about 0.5% w/v and at least one acidifying agent, wherein the NORS releases a therapeutically effective amount of gNO. The present invention also relates to a method for the treatment of a wound in a human, the method comprising administering to the human a liquid NORS comprised of at least one nitric oxide releasing compound and at least one acidifying agent, wherein the NORS provides an extended release of a therapeutically effective amount of gNO. The present invention also relates to a method for the treatment, prevention, or reduction of incidence of a disease or disorder in a human in need thereof, the method comprising administering to the human a liquid NORS comprised of at least one nitrite compound at a concentration of no greater than about 0.5% w/v and at least one acidifying agent, wherein the NORS releases a therapeutically effective amount of gNO.